국가: 오스트레일리아
언어: 영어
출처: Department of Health (Therapeutic Goods Administration)
lithium carbonate, Quantity: 250 mg
Aspen Pharmacare Australia Pty Ltd
Tablet, film coated
Excipient Ingredients: dextrin; lactose monohydrate; macrogol 6000; sodium starch glycollate type A; purified talc; sodium lauryl sulfate; magnesium stearate; hypromellose; maize starch
Oral
100, 200 tablets, 1000
(S4) Prescription Only Medicine
Mania, both as treatment and prophylaxis; manic depressive (bipolar) illness, both as treatment and as prophylaxis; it is less effective in depressive swings. In recurrent endogenous (unipolar) depressive illness, it is highly effective as prophylaxis in a number of cases, and is probably useful as treatment, especially if there is a family history of manic depressive illness and response to lithium. In some cases of schizoaffective illness and so called chronic schizophrenia it is dramatically effective. Those in the latter category who do respond have frequently had affective symptoms at some time. It is used in character or personality disorders in young people with clear evidence of cyclothymia. Lithium should not be prescribed until it is certain that the manic depressive swings are established and the course of the disease certain. If the patient has two affective swings in one year, perhaps in opposite directions, and associated with a positive family history, it should certainly be seriously considered. With three episodes in two years, there is no doubt it should be given. As a general rule, it should be prescribed, and therapeutic response assessed, satisfactory maintenance dosage determined, side and toxic effects and associated precautions discussed with the patient and relatives, and blood levels monitored, only under specialist supervision except perhaps in isolated areas. A major management problem also is that there are relatively narrow distances between the therapeutic and toxic dosages and blood levels. For these reasons treatment is preferably commenced on an inpatient basis, so that the patient is under appropriate observation.
Visual Identification: White to off-white oval-shaped bevel edged film coated tablets with breakline on one side and plain on the other side.; Container Type: Bottle; Container Life Time: 2 Years; Container Temperature: Store below 30 degrees Celsius
Licence status A
1994-07-21
LITHICARB ® 1 LITHICARB ® _Lithium carbonate _ CONSUMER MEDICINE INFORMATION (CMI) WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Lithicarb. It does not contain all the information that is known about Lithicarb. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Lithicarb against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT LITHICARB IS USED FOR Lithicarb is used to both treat and prevent episodes of a condition called manic-depressive or bipolar disorder, in which there are sustained mood swings either up (manic) or down (depression). It is also used in the treatment of schizo-affective illness and chronic schizophrenia. Lithicarb contains lithium (as lithium carbonate) as the active ingredient. Lithium is a powerful mood stabiliser, however, the exact way that lithium works to stabilise a person's mood is not known. It helps you to have more control over your emotions and helps you cope better. Your doctor, however, may have prescribed Lithicarb for another purpose. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY LITHICARB HAS BEEN PRESCRIBED FOR YOU. This medicine is available only with a doctor's prescription. There is no evidence that it is addictive. BEFORE YOU TAKE IT _WHEN YOU MUST NOT TAKE IT _ DO NOT TAKE LITHICARB IF YOU HAVE AN ALLERGY TO: • any medicine containing lithium • any of the ingredients listed at the end of this leaflet. Some of the symptoms of an allergic reaction may include shortness of breath, wheezing or difficulty breathing; swelling of the face, lips, tongue or other parts of the body; rash, itching or hives on the skin. DO NOT TAKE LITHICARB IF YOU HAVE OR HAVE HAD: • severe heart or kidney disease • low activity of the adrenal gland (e.g. Addison's disease) • an underactive thyroid g 전체 문서 읽기
LITHICARB- Product Information Page 1 of 10 AUSTRALIAN PRODUCT INFORMATION LITHICARB Lithium carbonate 1.NAME OF THE MEDICINE lithium carbonate 2&3. QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM White to off-white oval-shaped bevel edged film coated tablets, with breakline on one side and plain on the other side. Each LITHICARB tablet contains 250 mg of the active lithium carbonate. List of excipients with known effect: lactose. For the full list of excipients, see Section 6.1 List of excipients. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS The indications for lithium therapy may be summarised as follows: It is given for mania, both as treatment and prophylaxis; manic depressive (bipolar) illness, both as treatment and as prophylaxis; it is less effective in depressive swings. In recurrent endogenous (unipolar) depressive illness, it is highly effective as prophylaxis in a number of cases, and is probably useful as treatment, especially if there is a family history of manic depressive illness and response to lithium. In some cases of schizo-affective illness and so called chronic schizophrenia it is dramatically effective. Those in the latter category who do respond have frequently had affective symptoms at some time. It is used in character or personality disorders in young people with clear evidence of cyclothymia. Lithium should not be prescribed until it is certain that the manic depressive swings are established and the course of the disease certain. If the patient has two effective swings in one year, perhaps in opposite directions, and associated with a positive family history, it should certainly be seriously considered. With 3 episodes in two years, there is no doubt it should be given. As a general rule, it should be prescribed and therapeutic response assessed, satisfactory maintenance dosage determined, side and toxic effects and associated precautions discussed with the patient and relatives and blood levels monitored, only under specialist supervision except perhaps in isol 전체 문서 읽기